Market readiness, company capabilities and selecting a product with the right attributes are the three most important factors for securing a successful prescription-to-OTC switch, says Pfizer Inc.’s director of regulatory affairs for its Northern European cluster, Michelle Riddalls.
At the recent 13th Annual Ceuta International Alliance Conference in London, Riddalls told delegates that Pfizer had enjoyed “switch success”...
Welcome to HBW Insight
Create an account to read this article
Already a subscriber?